Ilaris "switches off" periodic syndromes in Phase III study
This article was originally published in Scrip
Novartis's injectable fully humanised monoclonal antibody, Ilaris (canakinumab) has been shown to send 90% of patients with cryopyrin-associated periodic syndromes (CAPS) into remission in a Phase III study, published in the NEJM online of June 4th.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.